Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label diagnostic study of NMK36 (fluciclovine (18F)) PET in suspected glioma
jRCT2080222934Phase 3Completed
- Sponsor
- Nihon Medi-Physics Co., Ltd.
- Start
- Aug 2015
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of fluciclovine f 18 in glioma, sponsored by Nihon Medi-Physics Co., Ltd. Primary endpoint: Diagnostic performance of NMK36 in depicting glioma lesions. Started Aug 2015; status: completed.
02
Drugs
fluciclovine f 18
03
Conditions
glioma
Beyond the preview
Go deeper on jRCT2080222934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222934.